| Document |
Document Title |
|
WO/2024/079647A1 |
The present invention relates to a composition comprising at least one psychedelic tryptamine, preferably derived from psychedelic psilocybin mushrooms, more preferably from psychedelic psilocybin mushrooms belonging to the Psilocybe gen...
|
|
WO/2024/052734A3 |
The application provides circular DNA vectors comprising promoters, scaffold matrix attachment region (S/MAR) sequences, and transgenes derived from proteins expressed in respiratory epithelium and which lack drug resistance genes. The a...
|
|
WO/2024/050285A3 |
Compositions and methods are provided for preventing or treating obesity and/or overweight, and managing body weight. Compositions comprise partial agonists of the leptin receptor (lepr), including variant leptin polypeptides, which part...
|
|
WO/2024/079224A1 |
The present disclosure relates to a stable aqueous composition of dalbavancin, the process for making such compositions and use of such compositions for treatment of a patient in need thereof.
|
|
WO/2024/079221A1 |
An isolated protein comprising (i) a first protein moiety selected from the group of proteins comprising an amino acid sequence having at least 70% identity to residues 113-231 of 5 Bri2 from human (SEQ ID NO: 2); and proteins comprising...
|
|
WO/2024/080398A1 |
The present invention relates to a peptide having activities to promote hair growth or to prevent or inhibit alopecia. The peptide of the present invention promotes the proliferation of hair follicle dermal papilla cells (HFDPC) and huma...
|
|
WO/2024/080482A1 |
The present invention relates to a composition for endometrial regeneration containing a uterus derived decellularized extracellular matrix (UdECM) and a manufacturing method therefor. Characterized by containing uterus derived decellula...
|
|
WO/2024/081276A1 |
The invention relates to compositions and methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody (e.g. pembrolizumab), or antigen binding fragment thereof, with or ...
|
|
WO/2024/081604A1 |
The present relates to polynucleotide constructs encoding an ApoE3 related protein optionally containing one or more intron. Potential uses of the different constructs include gene therapy targeting one or more disease or disorder, for e...
|
|
WO/2024/044679A3 |
This disclosure describes methods of site-specific modification of peptides for conjugation, and more particularly methods for synthesizing peptides with N-terminal cysteine and uses of the same.
|
|
WO/2024/078618A1 |
Disclosed in the present invention are a crystal form of a cyano-substituted polypeptide compound and a preparation method therefor. Specifically disclosed are a crystal form of the compound of formula (I) and a preparation method therefor.
|
|
WO/2024/077402A1 |
The present disclosure provides a matrix microneedle patch made of a hyaluronic acid (HA) polymeric backbone functionalized with dopamine (DA) and 4-amino-3-fluorophenylboronic acid (AFBA, pKa ~7.5) that quickly and spontaneously crossli...
|
|
WO/2024/079739A1 |
The present disclosure provides, among other things, methods and compositions for the oral administration of polypeptides. Many polypeptides are typically administered in liquid solutions by intravenous or subcutaneous injection. The pre...
|
|
WO/2024/079486A1 |
The disclosure relates to composite materials for controlled release, for example, for use in drug delivery. The disclosure also provides methods for making the composite materials, formulations comprising the composite materials, and us...
|
|
WO/2024/079738A1 |
The present disclosure provides, among other things, methods and compositions for the oral administration of polypeptides. Many polypeptides are typically administered in liquid solutions by intravenous or subcutaneous injection. The pre...
|
|
WO/2024/080824A1 |
The present invention relates to a novel GLP-1 receptor antagonist analogue and an acylated GLP-1 receptor analogue, and use thereof for preventing or treating congenital hyperinsulinemia or hypoglycemia.
|
|
WO/2024/078729A1 |
The use of Fc-tagged Pregnancy-specific glycoprotein 1 (PSG1-Fc) in a method of treatment of a tendon injury in a human, in which the PSG1 is administered by intra-tendon or peri-tendon injection, is described. Also described is the use ...
|
|
WO/2023/250520A3 |
Cancer metastasis is the leading cause of cancer related death and involves the spreading of the tumor to distant sites throughout the body. However, there are limited therapies which can effectively target this deadly process. One prote...
|
|
WO/2024/081227A2 |
The present invention provides novel irisin peptides (e.g, irisin glycosylation mutants and biologically active fragments thereof). Also provided are methods for preventing or reducing degeneration of dopaminergic neurons and/or preventi...
|
|
WO/2024/081793A1 |
Systems and methods related to drug delivery are provided. In one arrangement, a fluid is administered to a subject in drinkable form, which can partially or fully solidify in the stomach or another area of the gastrointestinal tract to ...
|
|
WO/2024/015853A3 |
Disclosed herein are fusion proteins comprising the CR3 domain of the low density lipoprotein (LDLR) and a polypeptide with phase behavior. Also provided herein are polypeptides with phase behavior. Additionally provided herein are metho...
|
|
WO/2024/079460A1 |
The present invention relates to novel polypeptide ligands of CXCR1 and/or CXCR2 which are derived from GCP2. The invention also concerns polynucleotides encoding the polypeptide ligands, uses of the polypeptide ligands and compositions ...
|
|
WO/2024/080854A1 |
The present disclosure relates to a fusion molecule is capable of binding to an antigenic substance of which an elevated level or excessive amount causes or results in an immunological disease and inducing phagocytosis, thereby removing,...
|
|
WO/2024/080399A1 |
The present invention relates to a peptide with the activity of promoting hair growth or preventing or inhibiting alopecia. The peptide of the present invention promotes the proliferation of human follicular dermal papilla cells (HFDPC),...
|
|
WO/2024/079067A1 |
The invention provides viral protease inhibitors having the general formula (I) wherein the variables are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compou...
|
|
WO/2024/031036A3 |
The present application provides IL-15 prodrugs comprising the masking polypeptide (MP) and the cleavable moiety (CM). The isolated nucleic acid molecules encoding the IL-15 prodrugs; vectors comprising the nucleic acid molecules; host c...
|
|
WO/2024/080402A1 |
The present invention relates to a peptide having activities of promoting hair growth or preventing or inhibiting hair loss. The peptide of the present invention has activities of promoting the proliferation of hair follicle dermal papil...
|
|
WO/2024/081940A2 |
The disclosure provides proteins that can be used as scaffolds to bind a specific target, including specific proteins or peptides of interest, as well as fusion proteins with the scaffolds. Such proteins or peptides of interest may inclu...
|
|
WO/2024/078534A1 |
An interfering RNA for inhibiting MLPH expression, which comprises: any one or more nucleotide sequences as shown in SEQ ID NOs: 1-20 or SEQ ID NOs: 27-38. The siRNA has good activity in inhibiting MLPH mRNA expression, with an inhibitio...
|
|
WO/2024/078588A1 |
A use of a compound represented by general formula (I) or a salt thereof in the preparation of a composition for skin aging repair, the skin aging repair comprising one or more of improving fibroblast activity, promoting keratinocyte pro...
|
|
WO/2024/035884A8 |
Disclosed herein are kits and methods for treating pulmonary arterial hypertension (PAH), comprising administering to a subject in need thereof: • a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically ...
|
|
WO/2024/080308A1 |
Disclosed is a composition containing a peptide, a specific type of surfactant, and a specific type of polymer.
|
|
WO/2024/081938A2 |
The disclosure provides proteins that can be used as scaffolds to bind a specific target, including specific proteins or peptides of interest, as well as fusion proteins with the scaffolds. Such proteins or peptides of interest may inclu...
|
|
WO/2024/081146A1 |
Provided are monoclonal antibodies that specifically bind to human precathepsin L, antigen-binding fragments thereof, and pharmaceutical compositions comprising the antibodies and fragments, as well as methods of treatment of sepsis, rhe...
|
|
WO/2024/079530A2 |
The application relates to nucleic acid regulatory elements that are able to enhance expression of genes constitutively in a variety of tissues, or in particular tissues including the muscle. The application further relates to methods em...
|
|
WO/2024/080401A1 |
The present invention relates to a peptide which promotes hair growth and prevents or inhibits hair loss. The peptide of the present invention promotes the proliferation of hair follicle dermal papilla cells (HFDPC) and human hair outer ...
|
|
WO/2024/078443A1 |
The present invention provides a combined nanodrug preparation, a preparation method therefor, and an application thereof, belongs to the technical field of biomedicine, and aims to solve the technical problem whereby it is quite difficu...
|
|
WO/2024/020537A3 |
Embodiments of the disclosure include methods and compositions in which NK cells are modified by the hand of man to express T-cell receptor and CD3 co-receptor on NK cells that do not naturally express them. Such modified NK cells work e...
|
|
WO/2024/081892A1 |
Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and/or...
|
|
WO/2024/081934A1 |
Described herein are methods and compositions for treating Alzheimer's Disease (AD), as well as compositions comprising a reelin-derived peptide and methods of use thereof.
|
|
WO/2024/081824A2 |
Example compositions, systems, devices, and methods are used for universal chimeric antigen receptor T (UCAR-T) cell therapy. An example method includes administering, to a subject, engineered immune cells that express a chimeric antigen...
|
|
WO/2024/080440A1 |
The purpose of the present invention is to provide a composition for preventing or treating neurodegenerative disorders, comprising humanin peptide as an active ingredient. When the humanin peptide of the present invention was administer...
|
|
WO/2024/081876A1 |
Extracellular vesicles (EVs) are natural liposome-like vesicles secreted by cells into the extracellular space. Provided herein are techniques to enrich cargo-loaded EVs over non-loaded EVs and contaminants. To achieve EVs were engineere...
|
|
WO/2024/011135A3 |
Aspects of the disclosure relate to oligonucleotides (e.g., RNAi oligonucleotides such as siRNAs) designed to target DUX4 RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, pa...
|
|
WO/2024/031045A3 |
The disclosed invention pertains and encompasses a composition comprising modified ASFV outer-membrane protein antigen mutants (termed dominant negatives) that exhibit non-binding affinity to RBCs while inducing an antibody-mediated resp...
|
|
WO/2024/079064A1 |
The invention relates to the field of transposases. In particular, it provides a polypeptide comprising or consisting of a Tc1/mariner superfamily transposase, e.g., a Sleeping Beauty transposase, having a substitution in amino acid posi...
|
|
WO/2024/010727A3 |
The present disclosure relates to cell growth supplements using dairy-based materials for cell culture and other applications. Some embodiments are directed to sequentially culturing cells in a culture medium comprising factors to increa...
|
|
WO/2024/077601A1 |
A peptide vaccine pharmaceutical composition and a method of use for stimulating immune responses against the glioma H3K27M mutation are provided. Having a length of at least 12 amino acid residues, the peptide vaccine is capable of stim...
|
|
WO/2024/044635A3 |
Conjugates comprising leukocyte-targeting molecules chemically conjugated to one or more active pharmaceutical agents are provided herein, as well as uses thereof.
|
|
WO/2024/079645A1 |
The present invention relates to a composition comprising at least one psychedelic not phosphorylated tryptamine, preferably derived from psychedelic psilocybin mushrooms, more preferably derived from psychedelic psilocybin mushrooms bel...
|
